Osteoarthritis - Pipeline Insight, 2025

DelveInsight's, "Osteoarthritis - Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Osteoarthritis: Understanding

Osteoarthritis: Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. Osteoarthritis is the most common type of arthritis, characterized by the gradual breakdown of cartilage in joints, leading to pain, stiffness, and swelling. Symptoms often include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after inactivity, and a sensation of joint instability or looseness. Affected joints may also produce a grinding or creaking sound during movement, and swelling can occur, particularly after prolonged use.

Osteoarthritis (OA) pathogenesis is a multifaceted process involving the entire joint, characterized by the interplay of various tissues such as articular cartilage, subchondral bone, synovium, and ligaments. Initially thought to be primarily a disease of cartilage, recent research reveals that OA is driven by complex mechanisms including mechanical stress, inflammation, and biochemical changes. Key factors in OA development include the activation of pro-inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-a), which contribute to cartilage degradation and synovial inflammation. Additionally, alterations in the extracellular matrix, increased production of matrix metalloproteinase (MMPs), and changes in subchondral bone remodeling play critical roles in the disease's progression. This holistic view underscores the need for targeted therapeutic strategies that address the multifactorial nature of OA, moving beyond traditional approaches focused solely on cartilage damage.

The diagnosis of osteoarthritis involves a comprehensive evaluation that includes a detailed medical history, physical examination, and imaging tests. Healthcare providers assess the patient's symptoms, such as joint pain, stiffness, and any mechanical issues like grinding sounds during movement. During the physical exam, the doctor examines the affected joints for swelling, tenderness, and range of motion. Imaging techniques, primarily X-rays, are utilized to identify characteristic changes such as joint space narrowing and the presence of osteophytes (bone spurs). In some cases, MRI or CT scans may be employed for a more detailed view of the joint structures. Treatment for osteoarthritis (OA) focuses on alleviating symptoms, improving joint function, and enhancing the quality of life. A comprehensive approach typically includes non-pharmacologic strategies such as physical therapy, which helps strengthen muscles around the joints and improve flexibility, and weight management to reduce stress on affected joints. Pharmacologic options include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation, as well as acetaminophen for mild pain.

"Osteoarthritis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

Osteoarthritis Emerging Drugs Chapters

This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteoarthritis Emerging Drugs

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis.

• EP-104IAR: Eupraxia Pharmaceuticals

Eupraxia's lead product candidate, EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia's patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• DFV890: Novartis

DFV890 is a small molecule, NOD-like receptor protein 3 (NLRP3) antagonist being developed by Novartis for the treatment of various inflammatory conditions. It is currently being evaluated in several phase I and II clinical trials, including studies in myeloid diseases, knee osteoarthritis, COVID-19, and cardiovascular disease. DFV890 works by inhibiting the NLRP3 protein, which plays a key role in the activation of the inflammatory response. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• 4P004: 4P-Pharma

4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties. 4P004 was developed in collaboration with the team of Prof. Francis Berenbaum and SATT Lutech. 4P004 is owned by 4P-Pharma's SPV - 4Moving Biotech. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

• GNSC 001: Genascence

GNSC-001 is a genetic medicine - a recombinant adeno-associated viral vector expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. Currently, the drug is in Phase I stage of its clinical trial for the treatment of OA.

Osteoarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Osteoarthritis
• There are approx. 100+ key companies which are developing the therapies for Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e. Phase III include, Biosplice Therapeutics.
• Phases

DelveInsight's report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.

Osteoarthritis Report Insights

• Osteoarthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteoarthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteoarthritis drugs?
• How many Osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biosplice Therapeutics
• Cynata Therapeutics
• Bone Therapeutics S.A
• Regeneron Pharmaceuticals
• Techfields Pharma
• Ampio Pharmaceuticals
• Asahi Kasei Pharma
• Taiwan Bio Therapeutics
• OliPass Corporation
• Bioventus
• Medipost
• LG Chem
• ICM Biotech
• Cells for Cells SA
• GWOXI Stem Cell Applied Technology
• UnicoCell Biomed
• Magellan Biologicals
• Levicept
• Arthrogen
• Personalized Stem Cells
• Peptinov
• Orient Europharma
• ZYUS Life Sciences
• Lubris Biopharma
• Saol Therapeutics
• Ageless Biotech
• Synartro AB
• Plakous Therapeutics
• Ribomic
• Meluha Therapeutics

Key Products

• Lorecivivint
• CYP 004
• JTA-004
• Fasinumab
• X0002
• Ampion
• AK1830
• Chondrochymal
• OLP-1002
• PTP-001
• SMUP-IA-01
• LG00034053
• ICM-203
• Cellistem
• GXCPC1
• Elixcyte
• Magellan Stem Cells
• LEVI 04
• ART-I02
• PSC-01
• PPV 06
• 2ccPA
• Trichomylin
• Human Lubricin
• SIL 1002
• Adipose dervied stem cells
• SYN321
• Protego-PD
• RBM-010
• Chondrogen